Clinical Research
Filter News
Found 130,560 articles
-
Surgeons from NYU Langone Health recently hit a major milestone in transplantation science after successfully attaching a pig's kidney to a human patient and watching it work for several hours.
-
eSight Announces Clinical Research Partnership with Ocular Health Centre’s EyeStart Inc.Collaboration with EyeStart to help develop the next generation of eSight devices
10/20/2021
Leading vision-enhancement platform, eSight, today announces a new research and development partnership with the Ocular Health Centre, one of Ontario’s top multi-doctor ophthalmology practices, and the cofounders of medical device incubator, EyeStart, Inc.
-
MorphoSys AG: First Patient Dosed in Phase 2 IGNAZ Study of Felzartamab in Patients with Immunoglobulin A Nephropathy
10/20/2021
MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that the first patient has been dosed in the Phase 2 IGNAZ clinical trial evaluating felzartamab for patients with Immunoglobulin A Nephropathy (IgAN).
-
TCR² Therapeutics Reviews Pipeline and Strategy at R&D Day
10/20/2021
TCR 2 Therapeutics Inc. today unveiled new programs and provided highlights from its emerging TRuC pipeline programs during its first virtual R&D Day.
-
Voyager Therapeutics Presents Positive Preclinical Data Supporting CNS-Directed GBA1 Gene Therapy at Virtual Congress of the European Society of Gene and Cell Therapy
10/20/2021
Voyager Therapeutics, Inc. today announced the presentation of preclinical data demonstrating a single intravenous (IV) dose of its novel GBA1 gene replacement therapy
-
OliX Pharmaceuticals Enters Agreement with Pharmaron to Advance Non-clinical Toxicology Testing for Hepatitis B Candidate OLX703A
10/20/2021
OliX Pharmaceuticals, Inc. today announced that the Company has selected Pharmaron to conduct non-clinical toxicity studies to evaluate the safety of OLX703A, OliX’s investigational therapeutic for hepatitis B (HBV).
-
Senhwa Presents Positive Initial Data from Phase 2 Clinical Trial of Silmitasertib (CX-4945) in Moderate COVID-19 Patients At the ISIRV-WHO Conference
10/20/2021
Senhwa Biosciences, Inc. today announced the positive efficacy and safety results from an investigator-initiated, Phase 2 clinical trial of Silmitasertib in approximately 20 patients with moderate COVID-19.
-
F-star Therapeutics Announces License Agreement with Janssen to Develop and Commercialize Multiple Next Generation Bispecific Antibody Therapeutics
10/20/2021
F-star Therapeutics, Ltd. today announced that it has entered into a license and collaboration agreement with Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson.
-
AmMax Bio Announces Positive Interim Phase 2 Results of AMB-05X for the Treatment of Tenosynovial Giant Cell Tumor (TGCT)
10/20/2021
AmMax Bio, Inc. today announced positive interim data from a Phase 2 study of AMB-05X for the treatment of tenosynovial giant cell tumor (TGCT).
-
BeyondSpring Pharmaceuticals Announces New Patient-Derived Cancer Model Data for Plinabulin Monotherpy at the AACR-NCI-EORTC Virtual International Conference
10/20/2021
Plinabulin’s anti-cancer effects were tested against approximately 80 patient-derived tumor models with small cell lung cancer (SCLC) tumor types being the most sensitive to plinabulin monotherapy at IC 70 of 35 nM
-
Numinus Advances Phase 1 Trial on Proprietary Psilocybin Product
10/20/2021
Numinus Wellness Inc. is pleased to have finalized the study design and protocol for a Phase 1 clinical trial on a naturally derived Psilocybin extract
-
BeiGene and Nanolek Announce Approval in Russia for BRUKINSA® (Zanubrutinib) for Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma
10/20/2021
BeiGene and Nanolek Announce Approval in Russia for BRUKINSA ® (Zanubrutinib) for Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma
-
Aatru Medical Announces Clinical Study and Interim Analysis of Their NPSIMS™ - Negative Pressure Surgical Incision Management System
10/20/2021
Oct. 20, 2021 13:00 UTC Aatru Medical, LLC ("Aatru") today announced the successful completion of the first 14 patients in their multi-center New Zealand-based clinical study of the FDA-approved NPSIMS™ Negative Pressure Surgical Incision Management System.
-
Axalbion Announces First Patients Treated in Phase 2 Clinical Trial in Chronic Cough with AX-8, a Novel TRPM8 Agonist
10/20/2021
Axalbion today announced that the first patients have been treated in a Phase 2 clinical study in chronic cough with AX-8, its lead compound. AX-8 is a potent and selective oral agonist of the transient receptor potential melastatin 8 (TRPM8) ion channel.
-
Enzychem Lifesciences Announces Positive Results for Phase 2 U.S. Study of EC-18 in Chemoradiation-Induced Oral Mucositis
10/20/2021
Enzychem Lifesciences (KOSDAQ: 183490) announced today positive Phase 2 results from a U.S. clinical trial of its lead candidate EC-18 in chemoradiation-induced oral mucositis (CRIOM).
-
Twist Bioscience Launches Exome 2.0 for Genomics Research
10/20/2021
Twist Bioscience Corporation today announced the launch of its Exome 2.0, featuring the most comprehensive coverage of protein-coding and noncoding
-
Chase Therapeutics Announces $20 Million Series B Financing to Advance Clinical Trials in Parkinson’s Disease and Major Depressive Disorder
10/20/2021
Chase Therapeutics Corporation today announced the completion of a milestone-based $20M Series B financing led by Chinalink Asia Holdings of Hong Kong.
-
Parse Biosciences Unveils 1,000,000 Cell scRNA-seq Kit
10/20/2021
Today at the annual American Society for Human Genetics meeting, Parse Biosciences , a company providing researchers with single-cell sequencing solutions, announced the launch of the most scalable single-cell RNA-seq solution on the market.
-
Immunome Announces Submission for Publication of Pre-clinical Research Detailing the Importance of Antibody Cocktail for SARS-CoV-2 Treatment and Prophylaxis
10/20/2021
Immunome, Inc. today announced that it submitted to bioRxiv a preprint of a manuscript regarding preclinical research of the company’s SARS-CoV-2 antibody cocktail, IMM-BCP-01.
-
Clinical Data from Editas Medicine’s Ongoing Phase 1/2 BRILLIANCE Clinical Trial of EDIT-101 for LCA10 to be Presented at the European Society of Gene and Cell Therapy Annual Congress
10/20/2021
Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that an abstract featuring initial clinical data from the BRILLIANCE clinical trial of EDIT-101 has been selected for an oral presentation at the 2021 European Society of Gene and Cell Therapy (ESGCT) Annual Congress being held virtually October 19 – 22, 2021.